Icon Bioscience

The company’s proprietary Verisome drug delivery technology is being used as the base for IBI-10090, for post-cataract surgery inflammation. The dexamethasone compound completed a pivotal phase 3 study (n=394), and based on these results, Icon plans to file an NDA by late 2015/early 2016. Phase 3 results builds on the phase 2b data, which showed a 50-60% clearance rate across all doses at Day 8.

Verisome is a “true liquid injection,” that binds the active drug to the carrier and can be administered with standard techniques. The technology allows for drug delivery in as short a duration as 1 week or as long as 9 months. Fully biodegradable, the carrier is eliminated as the drug is dispensed.

Also in the pipeline: A long-acting triamcinolone product that can be delivered with efficacy for up to 12 months. And a latanoprost product is in preclinical studies, with human studies expected to begin in 2015.

Participant:

David Tierney

David S. Tierney

David S. Tierney, M.D. is President and CEO of Icon Bioscience. Previously, Dr. Tierney was Co-Founder and President of Oceana Therapeutics, sold to Salix Pharmaceuticals in December 2011.

View Full Profile

STAY UP TO DATE WITH OIS

Get the Latest News, Podcasts and Videos.